H259 - 2023 Appropriations Act. (SL 2023-134)

Overview: Section 9E.17 of S.L. 2023-134 requires the Medicaid program to provide immediate coverage of new prescription medications treating serious mental illness that are approved by the Food and Drug Administration and available to the public, if the manufacturer of the medication is enrolled in the Medicaid Drug Rebate Program. For any of these new prescription medications that are eligible for inclusion on the Medicaid program's Preferred Drug List, the Department of Health and Human Services must submit, by the end of the next calendar quarter after the medication is available to the public, a proposal for consideration by the Preferred Drug List Policy Review Panel (Review Panel) regarding whether to include the medication on the Preferred Drug List. This section of the act also codifies previously enacted language establishing the Review Panel and requires the Review Panel to meet at least quarterly, rather than twice a year.

This section became effective October 3, 2023.